We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Have you been eager to see how Ventas, Inc. (VTR - Free Report) performed in Q4 in comparison with the market expectations? Let’s quickly scan through the key facts from this Chicago, IL-based healthcare real estate investment trust (REIT) earnings release this morning:
In-line FFO
Ventas came out with normalized funds from operations (FFO) per share of $1.03, meeting the Zacks Consensus Estimate.
Results reflect improved property performance and accretive investments.
How Was the Earnings Surprise Trend?
Ventas has a decent surprise history. Before posting the in-line Q4 FFO, the company delivered positive surprises in two of the trailing four quarters. In the other occasions, the company posted in-line results. This is depicted in the graph below:
Overall, the company surpassed the Zacks Consensus Estimate by an average of 0.73% in the trailing four quarters.
Revenues Came In Higher Than Expected
Ventas posted revenues of $895.3 million, which beat the Zacks Consensus Estimate of $878.6 million. Further, it compared favorably with the year-ago number of $875.7 million.
Key Developments to Note
During the year, Ventas funded investments of around $1.8 billion. It also realized approximately $700 million for the sale of 36 of its Kindred Healthcare, Inc skilled nursing facilities (SNFs).
The company exited the quarter with lower cash and cash equivalents. However, it currently has borrowing capacity of over $2.7 billion.
Ventas expects its 2018 normalized FFO per share outlook in the range of $3.95 – $4.05.
The company anticipates same-store cash net operating income growth of 0.5–2.0% in 2018.
What Zacks Rank Says
Ventas has a Zacks Rank #4 (Sell). However, since the latest earnings performance is yet to be reflected in the estimate revisions, the rank is subject to change. While things apparently look favorable, it all depends on what sense the just-released report makes to the analysts.
Check back later for our full write up on this VTR earnings report!
Note: Anything related to earnings presented in this write-up represent funds from operations (FFO) — a widely used metric to gauge the performance of REITs.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
Image: Bigstock
Ventas' (VTR) Q4 FFO Meets Estimate, Revenues Beat
Have you been eager to see how Ventas, Inc. (VTR - Free Report) performed in Q4 in comparison with the market expectations? Let’s quickly scan through the key facts from this Chicago, IL-based healthcare real estate investment trust (REIT) earnings release this morning:
In-line FFO
Ventas came out with normalized funds from operations (FFO) per share of $1.03, meeting the Zacks Consensus Estimate.
Results reflect improved property performance and accretive investments.
How Was the Earnings Surprise Trend?
Ventas has a decent surprise history. Before posting the in-line Q4 FFO, the company delivered positive surprises in two of the trailing four quarters. In the other occasions, the company posted in-line results. This is depicted in the graph below:
Ventas, Inc. Price and EPS Surprise
Ventas, Inc. Price and EPS Surprise | Ventas, Inc. Quote
Overall, the company surpassed the Zacks Consensus Estimate by an average of 0.73% in the trailing four quarters.
Revenues Came In Higher Than Expected
Ventas posted revenues of $895.3 million, which beat the Zacks Consensus Estimate of $878.6 million. Further, it compared favorably with the year-ago number of $875.7 million.
Key Developments to Note
During the year, Ventas funded investments of around $1.8 billion. It also realized approximately $700 million for the sale of 36 of its Kindred Healthcare, Inc skilled nursing facilities (SNFs).
The company exited the quarter with lower cash and cash equivalents. However, it currently has borrowing capacity of over $2.7 billion.
Ventas expects its 2018 normalized FFO per share outlook in the range of $3.95 – $4.05.
The company anticipates same-store cash net operating income growth of 0.5–2.0% in 2018.
What Zacks Rank Says
Ventas has a Zacks Rank #4 (Sell). However, since the latest earnings performance is yet to be reflected in the estimate revisions, the rank is subject to change. While things apparently look favorable, it all depends on what sense the just-released report makes to the analysts.
(You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.)
Check back later for our full write up on this VTR earnings report!
Note: Anything related to earnings presented in this write-up represent funds from operations (FFO) — a widely used metric to gauge the performance of REITs.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>